Cosmo Half-Year Report 2021
Cosmo Pharmaceuticals N.V. reports half-year results for the period ended 30 June 2021.
Cosmo obtained the first ever FDA approval for a device that uses artificial intelligence to help detect signs of colon cancer and announced important out-licencing agreements. As a consequence of the Cassiopea licencing deal announced on 26 July, Cosmo will be back to profit before tax in FY21.